Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

Schisandra chinensis

Plain-language summaryIntrigue 48 / 100

Schisandra (Chinese magnolia vine) berry is an adaptogen used in traditional Chinese medicine for stress, fatigue, and liver support. The lignans class drives the activity. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundGeneric nutrient

25/100

Well-characterized adaptogen lignan with diffuse mechanism and thin human evidence, outcompeted in every niche

Look, Schisandra chinensis has been in the Chinese pharmacopeia for centuries, and the bench literature has expanded correspondingly. But expanded doesn’t mean improved. The active constituents, the schizandrin lignans (schizandrin A, B, C, gomisin A, gomisin N, and a handful of others), are reasonably well characterized chemically, and theres a modestly sized body of work on hepatoprotection in rodent liver injury models. That’s the ceiling of the story, and it’s not a high ceiling.

The mechanism picture is diffuse to the point of frustration. Nrf2 pathway activation, antioxidant effects, HPA axis modulation, vague adaptogenic stress-tolerance framing: these are the kinds of multi-mechanism claims that look comprehensive on a monograph page but are hard to operationalize at the bench. The CYP3A induction activity is probably the most mechanistically specific angle, and that’s primarily relevant as a drug interaction liability, not a productive research target in itself.

The differentiation problem is real. Schisandra sits in a crowded adaptogen space alongside Rhodiola rosea, Withania somnifera, Eleutherococcus senticosus, and Panax ginseng. Each of those alternatives has at least one distinctive mechanistic claim or a more developed trial base. Rhodiola has the SHR-5 extract work and the partial MAO inhibition angle. Ashwagandha has the KSM-66 RCT series and a consistent cortisol signal. Schisandra’s hepatoprotective niche is real but contested by compounds with significantly better evidence: silymarin, TUDCA, NAC. On no single dimension does Schisandra clearly win.

On translational signal, the honest picture is thin. Human trials exist but are small, poorly blinded, and concentrated in Eastern European and Chinese research groups without independent replication. Effect sizes in stress-tolerance and endurance outcomes are modest and inconsistently reported across studies. We dont think the preclinical signal is fabricated; the schizandrins do interesting things in hepatocyte injury models. But the bench-to-clinic arrow is weak, and the question of whether those rodent outcomes generalize to meaningful human endpoints remains open in a way that’s not particularly exciting to work on right now.

For bench utility, Schisandra isn’t zero. If you’re running a lignan pharmacokinetics panel, building a CYP3A induction comparison, or designing a comparative adaptogen study that needs a reference compound, it has a slot. But thats a narrow role. A researcher designing a program around Schisandra specifically would struggle to justify that choice against the available alternatives, and we think most serious investigators already know that. The score reflects it.

Novelty

22

Mechanism promise

28

In-category differentiation

25

Evidence quality

28

Translational signal

25

Research bench value

22

Rationale Schisandra scores low on novelty (decades-old herb in a crowded adaptogen category) and differentiation (no clear superiority over Rhodiola, ashwagandha, or silymarin on any key metric); the schizandrin lignan profile is chemically interesting but translational evidence is thin and concentrated in single-consortium work without independent replication, placing the raw calculated score well below the OTC-herb cap.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Chinese magnolia vine berry adaptogen

A Chinese berry traditionally used as the ‘five flavors fruit’ for endurance, mental clarity, and hepatoprotection, characterized by schizandrins.

Abstract

Schisandra chinensis (Wu Wei Zi, “five flavors fruit”) is a climbing vine from China and Russia whose berries have been used for endurance, mental clarity, hepatoprotection, and longevity. The active constituents are lignans called schizandrins (schizandrin, gomisin A, gomisin N, and others). Modest hepatoprotective effects in liver injury models, antioxidant effects, and stress-tolerance effects have been documented. The schizandrins are CYP3A inducers, which has clinical drug interaction implications. Doses are typically 500 to 2000 mg per day of berry extract.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-115Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Mucuna pruriens

Plain-language summaryIntrigue 58 / 100

Mucuna pruriens (velvet bean) is a tropical legume with high concentrations of L-DOPA, the direct precursor to dopamine. Used in Ayurveda and as a natural Parkinson disease aid. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

26/100

Natural L-DOPA source with thin pharmacokinetic differentiation and limited bench utility

Look, Mucuna pruriens is essentially a vehicle for L-DOPA delivery, and L-DOPA has been a therapeutic compound since the 1960s. The mechanism isn’t novel – dopamine precursor supplementation is textbook neurochemistry. What makes Mucuna interesting at all is the question of whether the plant matrix changes how that L-DOPA behaves in practice, and honestly, that question is still mostly unanswered.

The small Parkinson trials comparing Mucuna to carbidopa-levodopa are real data points. A handful of studies, primarily from Tharayil et al. and a few Indian groups, found broadly similar motor benefit at equivalent L-DOPA content. Some reports suggest slower onset and potentially longer duration of effect compared to standard formulations. If that pharmacokinetic story holds up it would be genuinely interesting – but the evidence base is thin and uncontrolled. Trials are underpowered, and the variability in L-DOPA content across preparations makes dose-matching unreliable enough to compromise any clean mechanistic conclusion.

What we dont find compelling is the bench research angle. An investigator studying dopaminergic pharmacology, Parkinson pathology, or L-DOPA-induced dyskinesia is going to reach for pharmaceutical-grade levodopa every time. The reproducibility problems with botanical extracts – lot-to-lot variation in L-DOPA content, presence of uncharacterized alkaloids, NADH and putative monoamine oxidase activity from co-extractants – are liabilities in a controlled research context, not assets. The “other constituents” story gets cited occasionally but no specific pharmacologically active fractions have been rigorously characterized or isolated in replicated work.

From a novelty standpoint, Mucuna’s L-DOPA content was characterized in the 1930s and the Ayurvedic use predates that by centuries. Thats not a knock on its own – old compounds can find new relevance – but there isnt a new mechanism story here, no surprising receptor interaction, no novel target class that would organize a research program specifically around this plant.

We think the only genuinely interesting research question Mucuna opens up is the PK comparison to synthetic formulations, and specifically whether the natural matrix affects tolerability or dyskinesia burden in PD management. That question has clinical relevance and is underserved in the literature. At bench scale, though, utility is limited. Researchers interested in L-DOPA pharmacology have better-controlled tools; researchers interested in botanical ethnopharmacology have more scientifically active targets. Mucuna sits in an awkward middle ground – a well-understood drug dressed as an herb, without the quality control of the former or the novelty of the latter.

Novelty

18

Mechanism promise

20

In-category differentiation

20

Evidence quality

35

Translational signal

45

Research bench value

20

Rationale Mucuna pruriens is fundamentally a botanical L-DOPA delivery system built around a 60-year-old therapeutic mechanism; the small comparative PD trials demonstrate equivalence to synthetic formulations rather than superiority, and lot-to-lot variability in L-DOPA content makes it an unreliable research tool compared to pharmaceutical-grade levodopa.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Velvet bean / L-DOPA source

A tropical bean traditionally used in Ayurveda for Parkinsonian symptoms, the natural source of L-DOPA used as standardized extracts containing 15 to 50 percent L-DOPA.

Abstract

Mucuna pruriens (velvet bean, kapikacchu) is a tropical legume used in Ayurvedic medicine for Parkinsonism, infertility, and “vata” disorders. The seeds contain L-DOPA (L-3,4-dihydroxyphenylalanine) at 5 to 7 percent of seed weight, the highest natural concentration known. Standardized extracts contain 15 to 50 percent L-DOPA depending on processing. The compound has been compared with synthetic L-DOPA in small Parkinson disease trials with broadly similar efficacy at equivalent L-DOPA content; some reports suggest slower onset and longer duration than carbidopa-levodopa formulations, possibly due to other constituents that influence pharmacokinetics. The compound is sold as a dietary supplement; doses are typically 500 to 2000 mg of extract standardized to 15 to 50 percent L-DOPA. Use for Parkinson disease should be supervised; the supplement market includes preparations with insufficient L-DOPA content for therapeutic use and potential misuse for non-Parkinson recreational dopaminergic effects.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-116Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
PQQ (Pyrroloquinoline Quinone)

Plain-language summaryIntrigue 60 / 100

PQQ (pyrroloquinoline quinone) is a redox cofactor found in plants and bacteria that may stimulate mitochondrial biogenesis (creation of new mitochondria). Sold as a longevity and energy supplement. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

35/100

A mature bacterial redox cofactor with an interesting mitochondrial story that human evidence never fully validated

Look, PQQ has been in the research conversation long enough that calling it a frontier compound is a stretch. The bacterial dehydrogenase work goes back to the 1980s, and the mammalian mitochondrial biogenesis story picked up in the early 2000s after some elegant deficiency-repletion work in mice. Its a genuinely interesting setup. The problem is what happened next.

The mechanism is the compound’s strongest asset. PQQ cycles through redox states faster than vitamin C and with more catalytic capacity than most dietary antioxidants, and the downstream signaling through NRF2 and PGC-1alpha gives it more to say than just “antioxidant.” The biogenesis angle is real: chronic PQQ deficiency in rodents produces mitochondrial dysfunction phenotypes that reverse on repletion. We like that the mechanism has multiple plausible entry points, and the chemistry is genuinely unusual for a dietary-origin compound. That’s worth noting.

What we dont like: fifteen-plus years of research interest and the human trials are still small, the effect sizes modest, the replication incomplete. Cognitive function, fatigue, and cardiovascular endpoints have all been probed in small cohorts with some signal, but not the kind of signal that reorganizes a research program. The NRF2 and PGC-1alpha pathways are crowded now. Urolithin A, NAD precursors like nicotinamide riboside, and several mitochondria-targeted peptides have moved into the same territory with arguably cleaner pharmacology and stronger human translation. PQQ doesnt clearly win any dimension of that comparison.

The bench utility is real but specific. If your program involves dietary-origin redox cofactors in mitochondrial function, or probing PGC-1alpha activation by a small molecule with a plant-food sourcing history, PQQ earns its place in the toolkit. The BioPQQ trademarked product has reasonable characterization and reproducible sourcing, which matters for experimental consistency. But as a general mitochondrial biogenesis probe, theres more compelling options with cleaner pharmacology and better-defined target engagement.

Honestly, this compound fits the profile of many redox and mitochondrial-adjacent supplements that generated real excitement a decade ago and have since settled into the “interesting but unproven” column. The mechanism remains incompletely characterized, which after this many years of study is more liability than intrigue. Worth tracking for programs specifically touching dietary-origin redox biology or NRF2 activation in aging contexts, not a compound to build a research program around.

Novelty

32

Mechanism promise

45

In-category differentiation

28

Evidence quality

33

Translational signal

35

Research bench value

42

Rationale PQQ earns points on mechanism interest (NRF2 + PGC-1alpha + high-capacity redox cycling is a real multi-target story) but loses heavily on novelty (the mitochondrial biogenesis angle is fifteen-plus years old), thin human evidence with modest effect sizes, and weak differentiation in a now-crowded mitochondrial space. Bench utility exists but is narrow and not irreplaceable.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Redox cofactor

A bacterial redox cofactor and putative mitochondrial biogenesis enhancer found in trace amounts in plant foods, sold as a dietary supplement.

Abstract

Pyrroloquinoline quinone (PQQ; CAS 72909-34-3; molecular formula C14H6N2O8; molecular weight 330.21) is a redox cofactor present in bacterial dehydrogenases and in trace amounts in plant foods (kiwi, parsley, green tea, fermented soy). PQQ has been studied as a putative mitochondrial biogenesis stimulant; chronic dietary PQQ deficiency in mice produces mitochondrial dysfunction phenotypes that are reversed by repletion. The compound has been studied for cognitive function, fatigue, and cardiovascular endpoints in small human trials with modest effect sizes. Mechanism is incompletely characterized; proposed activities include direct redox cycling, NRF2 pathway activation, and PGC-1alpha-mediated mitochondrial biogenesis. Doses are typically 10 to 40 mg per day. The compound is sold as a dietary supplement (BioPQQ).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-119Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Coenzyme Q10 (Ubiquinol)

Plain-language summaryIntrigue 60 / 100

Coenzyme Q10 (ubiquinol when reduced) is an essential mitochondrial cofactor that participates in the electron transport chain. Levels decline with age and with statin use. Used as a heart-failure supplement and for energy. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Endogenous mitochondrial cofactor

An endogenous redox cofactor of the mitochondrial electron transport chain, declining with age and statin use, sold as a dietary supplement.

Abstract

Coenzyme Q10 (CoQ10, ubiquinone; CAS 303-98-0; molecular formula C59H90O4; molecular weight 863.34) is an endogenous redox cofactor essential for mitochondrial electron transport between Complex I/II and Complex III. The compound is synthesized from tyrosine and the mevalonate pathway; statin use reduces endogenous synthesis through HMG-CoA reductase inhibition (the same pathway used for cholesterol synthesis). Plasma and tissue CoQ10 decline with age. Supplementation has been studied for cardiovascular function (heart failure, hypertension), statin-associated muscle symptoms, and migraine prophylaxis. Bioavailability of the oxidized form (ubiquinone) is poor; the reduced form (ubiquinol) has 3- to 5-fold better bioavailability and is the preferred supplemental form for elderly subjects with reduced redox capacity. Doses are typically 100 to 400 mg per day of ubiquinol or higher of ubiquinone.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-120Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Idebenone

Plain-language summaryIntrigue 65 / 100

Idebenone is a synthetic CoQ10 analog with better blood-brain barrier penetration. Approved in Europe (Raxone) for Leber hereditary optic neuropathy, a rare mitochondrial eye disease. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

47/100

EU-approved Complex I bypass agent with a validated niche in LHON but failed broader neurodegeneration ambitions

Look, idebenone has something most compounds in this library will never have: a European Medicines Agency approval. Raxone is the recognized pharmacological option for Leber hereditary optic neuropathy, a rare mitochondrial complex I disease that produces acute bilateral vision loss in young adults. That regulatory standing is not performative. The mechanism is tested and clinically anchored in a defined population, and thats worth acknowledging up front before we talk about where it falls short.

The core chemistry was developed by Takeda in the 1980s. The short-chain ubiquinone design, replacing CoQ10’s isoprenoid tail with a hydroxyalkyl chain, substantially improves water solubility and, critically, allows idebenone to function as an electron carrier from cytosolic NADH directly to Complex III, bypassing dysfunctional Complex I entirely. In LHON, where Complex I point mutations block normal electron flow and kill retinal ganglion cells, that bypass is the therapeutic logic. The RHODOS trial established meaningful visual acuity preservation in recently affected eyes, and subsequent long-term observational data has held up reasonably well. Mechanism and clinical outcome are genuinely coherent here.

What we don’t like: the broader bets on idebenone have not paid. The Alzheimer program ran through multiple European consortium trials across the 1990s and 2000s, including a reasonably powered study published in 2003 by Gutzmann and colleagues, and produced results that weren’t compelling enough to generate regulatory interest. The Friedreich ataxia program shows some modest cardiac and neurological endpoint signal but no approval. The DELOS trial in Duchenne muscular dystrophy produced a respiratory rate-of-decline signal that remains inconclusive and hasn’t led anywhere definitive. Each new indication gets a plausible rationale and lands in the modest-to-inconclusive range. Thats a pattern.

Against the modern mitochondrial pharmacology landscape, idebenone also faces more interesting competition. SS-31 targets cardiolipin at the inner mitochondrial membrane via a mechanism idebenone doesn’t touch. MOTS-c drives mitochondrial-nuclear retrograde signaling through AMPK and is genuinely novel as a compound class. MitoQ uses triphenylphosphonium conjugation to concentrate at the inner membrane, a more targeted delivery strategy than the water-soluble ubiquinone scaffold. Idebenone’s design was clever for its era; it’s harder to call it differentiated now.

As a bench tool the compound is legitimately useful. Extensive PK data exists, the dose-response literature in cell lines and animal models is well-characterized, and it’s a clean experimental handle for studying Complex I bypass pharmacology in disease-relevant contexts. If your research program involves mitochondrial electron transport dysfunction, idebenone gives you something real to work with. We’d score it higher if the broader program had materialized or if the mechanism were more contemporary. It didnt, and it isn’t, so here we are at 47.

Novelty

25

Mechanism promise

48

In-category differentiation

50

Evidence quality

60

Translational signal

55

Research bench value

52

Rationale Idebenone earns real credibility from EMA approval for LHON and a mechanistically sound electron-shuttle story, but its 1980s origins, Alzheimer program failures, and the emergence of more mechanistically novel mitochondrial compounds keep novelty and differentiation scores firmly mid-range.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic ubiquinone analog

A short-chain synthetic ubiquinone analog approved in Europe for Leber hereditary optic neuropathy, with reduced lipophilicity and better water solubility than CoQ10.

Abstract

Idebenone (Raxone, Catena, Sovrima; CAS 58186-27-9; molecular formula C19H30O5; molecular weight 338.44) is a synthetic short-chain ubiquinone analog with the 10-carbon isoprenoid tail of CoQ10 replaced by a 10-carbon hydroxyalkyl chain. The structural modification substantially increases water solubility while preserving the redox-cycling quinone chemistry. The compound is approved in Europe (Raxone) for Leber hereditary optic neuropathy, a mitochondrial complex I disease producing acute optic neuropathy. Idebenone bypasses dysfunctional Complex I by directly transferring electrons from cytosolic NADH to Complex III. The compound has also been studied in Alzheimer disease (mixed results, did not advance to FDA approval), Friedreich ataxia (modest effects, no approval), and Duchenne muscular dystrophy. Doses are 900 mg per day in three divided doses for LHON.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-121Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Methylene Blue

Plain-language summaryIntrigue 75 / 100

Methylene blue is a phenothiazine dye used historically for malaria, methemoglobinemia, and septic shock. At low doses it serves as an alternative electron donor in mitochondria, supporting energy production when normal pathways are impaired. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

53/100

Old phenothiazine with a genuine low-dose mitochondrial story; speculative cognitive signal but solid bench utility

Look, methylene blue is a weird one. It’s the oldest synthetic pharmaceutical compound still in active use, first synthesized in 1876, and its continued relevance is more interesting than its history suggests. The thing that matters for modern research isn’t the methemoglobinemia indication or the old antimalarial work. It’s the low-dose electron-cycling story, and thats worth taking seriously.

Here’s the mechanism as best we understand it: at low doses, methylene blue acts as an electron donor to Complex III of the mitochondrial electron transport chain, bypassing dysfunctional Complex I and Complex II. For conditions where mitochondrial dysfunction is upstream of neurodegeneration, that’s a genuinely useful probe mechanism, not a hand-wavy “supports mitochondria” claim. The Gonzalez-Lima group at UT Austin has published the most credible low-dose cognitive work, documenting improvements in rodent models of TBI, aging, fear extinction, and memory consolidation. The compound also appears to inhibit tau aggregation through a separate pathway, which is what pulled it into the Alzheimer’s space as a therapeutic candidate and gave it a second mechanistic identity worth tracking independently.

Dose-dependence here is important and a bit tricky to work around experimentally. High doses produce MAO inhibition and real serotonin syndrome risk, which complicates stack protocols and confounds signal if youre not careful about where you sit on the curve. Low-dose experiments need to be precisely calibrated. The blue staining effect on tissues and excreta is cosmetically obvious and can unmask participant blinding in clinical trials, a methodological headache that’s shown up more than once in the published discussion sections.

On the clinical side: the TauRx program used leucomethylthioninium, a reduced form, in phase 2 and phase 3 Alzheimer’s trials. Phase 2 signal was real and drew serious attention. Phase 3 confirmation was inconsistent. That outcome puts methylene blue in a familiar position: multi-lab preclinical is solid, small-N human cognitive signal exists but is modest, and replication is still genuinely in progress across several independent groups.

What we actually like here is the bench utility. Methylene blue is cheap, readily sourced at pharmaceutical grade, and provides a clean pharmacological tool for probing mitochondrial redox biology. If you’re building experiments around mitochondrial dysfunction in neurodegeneration, this belongs in the toolkit. We don’t think it’s a frontier compound, and we don’t think the cognitive signal is anywhere near settled. But it earns its place as a niche probe with a real mechanistic story and a well-characterized profile that makes it genuinely useful as a research instrument.

Novelty

40

Mechanism promise

65

In-category differentiation

55

Evidence quality

50

Translational signal

45

Research bench value

65

Rationale Ancient compound elevated by a mechanistically credible low-dose electron-donor story; preclinical is multi-lab and solid but the human cognitive signal remains modest and contested, placing it firmly in niche-probe territory rather than the novel-frontier tier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Phenothiazine dye / electron donor

A phenothiazine dye used historically as an antimalarial and methemoglobinemia treatment, with mitochondrial electron-cycling activity at low doses for cognitive applications.

Abstract

Methylene blue (methylthioninium chloride; CAS 61-73-4; molecular formula C16H18ClN3S; molecular weight 319.85) is a phenothiazine dye with the longest pharmaceutical history of any synthetic compound (first synthesized 1876). The compound is FDA-approved for methemoglobinemia (high-dose, 1-2 mg/kg IV) and has historical use as an antimalarial. Low-dose methylene blue (0.5 to 4 mg/kg orally) has been studied for cognitive enhancement, traumatic brain injury, and Alzheimer disease, based on the compound’s mitochondrial electron-cycling activity (donates electrons to Complex III, bypassing dysfunctional Complex I/II). Pharmacology is complex and dose-dependent; high doses produce MAO inhibition and serotonin syndrome risk. Low-dose cognitive applications use 5 to 20 mg orally. The compound stains tissues and excreta blue, which is cosmetically obvious but harmless.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-122Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
DSIP (Delta Sleep Inducing Peptide)

Plain-language summaryIntrigue 60 / 100

DSIP (delta sleep-inducing peptide) is a 9-amino-acid neuropeptide that consolidates deep slow-wave sleep. Used historically in research as a sleep aid, particularly for opioid withdrawal. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

30/100

Endogenous sleep nonapeptide with uncharacterized mechanism and five decades of modest, variable results

Look, DSIP has a great origin story. The Schoenenberger-Monnier group pulls a nonapeptide out of rabbit cerebral venous blood during slow-wave sleep in 1977, names it Delta Sleep Inducing Peptide, and you’d think the field was off to the races. Forty-seven years later we’re still arguing about what receptor it binds, what signaling it drives, and whether the sleep effect is real or an artifact of model selection. Thats not a good sign for a compound this old.

The mechanism problem is the core issue here. Most peptides that have stayed in the literature this long have at least earned a defined receptor or downstream target. DSIP hasn’t. Binding sites are unconfirmed, downstream effectors are hypothesized rather than demonstrated, and the endogenous plasma and CSF concentrations oscillate with circadian rhythm in ways that suggest a role in sleep architecture but don’t specify it. We’d normally credit a compound for having a novel, incompletely understood mechanism when the incompleteness is recent. Here it’s not recent; it’s just unresolved after decades of work, which is a different thing entirely.

The clinical record is thin and honest about its thinness. The alcohol and opioid withdrawal studies from the 1980s and 90s showed some signal, but the designs were small, controls were inconsistent, and follow-up replication never materialized in a serious way. The chronic pain work is similarly suggestive without being convincing. Even the sleep effect itself, which is literally in the name, comes out as modest and variable across independent labs. When your flagship claim can’t reliably replicate over five decades, you have to question whether the effect is real at the doses studied or real only in specific species or preparation conditions.

Where we do give DSIP some credit is as a target for investigators specifically working on endogenous neuropeptide contributions to sleep regulation and stress response. It’s one of the few characterized endogenous peptides with proposed roles across sleep, circadian gating, and HPA-axis modulation, even if none of those roles are well-defined mechanistically. If your lab is trying to map what the brain does to signal sleep onset at the peptide level, DSIP is a legitimate object of study. It’s just not a tool you’d trust as a probe for a defined pathway, because the pathway isn’t defined.

Honestly, DSIP is a compound the field has never quite given up on and never quite validated. The score reflects that honestly.

Novelty

30

Mechanism promise

22

In-category differentiation

22

Evidence quality

38

Translational signal

30

Research bench value

40

Rationale DSIP scores low primarily because its mechanism remains undefined after 47 years of study, its flagship effect is conceded to be modest and variable even by its proponents, and it has been outcompeted in every clinical indication it touched. The bench value credit is real but limited: as a probe for endogenous sleep-regulatory neuropeptide signaling it’s interesting in principle, but you can’t use an uncharacterized binding site as a reliable experimental handle.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Nonapeptide neuropeptide

An endogenous nonapeptide isolated from rabbit cerebral venous blood with sleep-promoting and stress-modulating activity.

Abstract

DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu; CAS 62568-57-4; molecular weight 848.81) is a nonapeptide isolated in 1977 by the Schoenenberger-Monnier group from rabbit cerebral venous blood collected during electrically induced slow-wave sleep. The compound is endogenously present in mammalian brain and plasma, with proposed roles in sleep regulation, stress response, and circadian rhythm modulation. Despite the name, the sleep-promoting effect is modest and variable across studies. Mechanism is incompletely characterized; binding sites and downstream signaling have not been definitively established. The compound has been studied in alcohol withdrawal, opioid withdrawal, and chronic pain. Administered subcutaneously or intranasally; oral bioavailability is poor. Research-grade doses are typically 100 to 500 micrograms per administration.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-123Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
P21 (Cerebrolysin-derived peptide)

Plain-language summaryIntrigue 65 / 100

P21 is a synthetic peptide derived from ciliary neurotrophic factor (CNTF) developed for neuroprotection and neurogenesis. Used in research for memory and Alzheimer disease investigations. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

45/100

Mechanistically coherent neurogenic peptide stuck behind a single-lab evidence wall

Look, P21 has one thing going for it that cerebrolysin itself never could: it’s an actual molecule. Seven amino acids, defined sequence, definable dose. When Khalid Iqbal’s group at the New York State Institute for Basic Research pulled this peptide out of the active fraction and pinned it to a CNTF-receptor-related mechanism driving dentate gyrus neurogenesis, that was genuinely useful work. Adult hippocampal neurogenesis is a serious research target, and having a defined peptide that demonstrably stimulates it in rodent models is not nothing.

The mechanism is what we find most interesting here. CNTF receptor signaling in the context of adult neurogenesis is a real frontier. P21 appears to operate through pathways related to the CNTF receptor complex, producing dose-dependent increases in new neuron formation in the dentate gyrus and corresponding improvements in spatial learning and memory in aged and AD-model rodents. That’s a coherent story. It’s not a trivial “more BDNF” hand-wave; theres a specific receptor angle with specific behavioral readouts, and the ciliary neurotrophic factor pathway is mechanistically distinct from the BDNF/TrkB axis that most neurogenic compounds lean on.

Here’s the problem: it’s still basically one group, one lab. Iqbal’s work on P21 spans several papers and the lab has real credibility in the AD field, but external replication is thin. We haven’t seen multi-lab confirmation of the neurogenesis effect or independent validation of the CNTF-receptor mechanism at scale. The animal models are relevant — transgenic AD mice and cognitively aging rodents are the right system for these claims — but rodent-to-human translation in neurogenesis research has historically been brutal. The dentate gyrus neurogenesis story itself is contested in humans in ways it simply isn’t in rodents.

There’s also no human data. None. No phase 1, no small-N pilot, not even a case series. For a compound with this much mechanistic specificity, thats a notable gap. Pharmacokinetics in humans are essentially unknown, and we dont know whether intranasal or subcutaneous administration delivers meaningful CNS levels in a primate brain at any practical dose.

What P21 does offer is genuine bench utility as a CNTF-pathway probe for investigators working in adult neurogenesis or AD-related cognitive biology. If you’re running hippocampal slice work or transgenic rodent behavioral studies, P21 is a more tractable tool than cerebrolysin’s poorly-defined mixture. That’s real value, just narrow. We think this sits as a solid single-lab story worth watching but not worth centering a program on until someone outside the Iqbal consortium picks it up and replicates the core findings independently.

Novelty

55

Mechanism promise

58

In-category differentiation

48

Evidence quality

28

Translational signal

30

Research bench value

42

Rationale P21 earns real marks for its defined CNTF-receptor mechanism and dentate gyrus neurogenesis signal in AD rodent models, but the evidence base is almost entirely Iqbal’s group at NY State IBR with no meaningful external replication and zero human data; single-lab preclinical only holds the overall to 45.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

CNTF-derived neurogenic peptide

A short peptide derived from a cerebrolysin fraction with documented hippocampal neurogenesis activity in animal models.

Abstract

P21 is a peptide of the sequence Ala-Asp-Asn-Phe-Val-Phe-Lys derived from the active fraction of cerebrolysin (or related neurotrophic preparations) and identified by Khalid Iqbal’s group at the New York State Institute for Basic Research. The compound stimulates neurogenesis in the dentate gyrus through a CNTF-receptor-related mechanism, producing dose-dependent improvements in spatial learning and memory in rodent models of cognitive aging and Alzheimer disease pathology. The compound has not been advanced to human clinical trials. Pharmacokinetics are poorly characterized in humans. The compound is sold as a research peptide; investigational doses parallel cerebrolysin range scaled to peptide content.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-124Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Davunetide (NAP)

Plain-language summaryIntrigue 65 / 100

Davunetide (NAP) is an 8-amino-acid peptide derived from activity-dependent neuroprotective protein (ADNP). It supports microtubule integrity in neurons. Phase 2/3 trials in progressive supranuclear palsy were inconclusive. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

44/100

Interesting ADNP-derived tau biology probe that failed its pivotal PSP trial but retains real bench utility

Look, the honest framing on davunetide is this: it had a serious shot, it swung, and it missed. Allon Therapeutics ran a genuine pivotal trial in progressive supranuclear palsy, a devastating tauopathy with almost no treatment options, and the 2012 primary cognitive endpoint came back negative. The development program was shuttered. That’s not a single-lab anecdote gone sideways; thats a well-resourced Phase 2/3 effort that produced a definitive answer for the PSP indication. Researchers need to hold that fact in one hand before they do anything else with this compound.

The underlying biology is a different story, and it’s genuinely worth knowing. Davunetide is an eight-amino-acid fragment of ADNP, activity-dependent neuroprotective protein, which is a zinc-finger protein with a critical SIP box motif that interacts directly with microtubule-end binding proteins. The idea is that NAP stabilizes EB1/EB3-tubulin interactions and in doing so slows the hyperphosphorylation and aggregation of tau. That’s a plausible and fairly specific mechanism. Multiple labs, not just the originating Gozes group in Tel Aviv, have reproduced effects in rodent tauopathy models, including APP-PSEN1 mice and P301L transgenic lines. The preclinical corpus is solid enough to take seriously.

What we find interesting right now is the ADNP syndrome angle. ADNP haploinsufficiency causes a syndromic intellectual disability with autistic features, and the field has produced a handful of publications over the past three years examining whether NAP peptide can rescue ADNP-syndrome mouse phenotypes. The Gozes lab has continued publishing in this direction, and there are now independent replication attempts from other groups. It’s early, the N is tiny, and we haven’t seen a structured human signal, but the translational question is at least reformulated in a way that isn’t capped by the PSP failure.

As a bench tool, davunetide has real value for anyone studying microtubule dynamics in neurons, tau biology, or ADNP-interactome questions. The intranasal delivery pharmacokinetics are unusually well-characterized for a research peptide, partly because of the clinical program. Researchers have a reasonably solid CNS exposure profile to work from. Sourcing is more accessible than it was, and the peptide is structurally simple enough that vendor quality is easier to verify by HPLC than for larger fragments.

We dont think this belongs near the top of anyone’s list unless they’re specifically working the ADNP biology or designing tauopathy assays that need a reasonably specific microtubule-protective control. For those investigators, its genuinely useful. For everyone else, the failed pivotal trial is load-bearing information and the translational arrow is, at best, pointing sideways.

Novelty

48

Mechanism promise

52

In-category differentiation

38

Evidence quality

48

Translational signal

28

Research bench value

50

Rationale Davunetide scores modestly across the board because its development program ended on a clean negative result in a well-powered Phase 2/3 PSP trial (2012), crushing its translational signal even though the preclinical mechanistic work is real and multi-lab. What keeps it from falling further is the renewed relevance of ADNP biology through ADNP syndrome research and the compound’s continued utility as a probe for microtubule dynamics and tau pathology in preclinical models.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

ADNP-derived octapeptide

An eight-amino-acid fragment of activity-dependent neuroprotective protein (ADNP) studied in tauopathies and PSP.

Abstract

Davunetide (NAP, AL-108; Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln; CAS 173308-60-2; molecular weight 824.94) is an octapeptide derived from activity-dependent neuroprotective protein (ADNP). The peptide preserves microtubule integrity and reduces tau pathology in animal models of tauopathy. Davunetide was developed by Allon Therapeutics and advanced through Phase 2/3 trials in progressive supranuclear palsy (PSP); the pivotal trial in 2012 was negative for the primary cognitive endpoint, ending the development program. The compound is administered intranasally (the primary route of delivery to CNS for the formulation used in trials). Research-grade doses are 5 to 30 mg intranasally per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-125Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Carbamazepine

Plain-language summaryIntrigue 60 / 100

Carbamazepine (Tegretol) is a first-generation anticonvulsant from Geigy, synthesized in 1953 and FDA-approved in 1968. It blocks voltage-gated sodium channels much like lamotrigine and is broadly effective for partial seizures, trigeminal neuralgia (where it is first-line), and bipolar mania. Its big practical headache is potent induction of the liver enzyme CYP3A4, which means it accelerates the breakdown of many other drugs (oral contraceptives, warfarin, many antidepressants), creating constant interaction problems. It also induces its own metabolism, so doses often need to climb in the first few weeks. The active leftover is a structurally similar epoxide that contributes to both the therapeutic effect and the side effects. Aplastic anemia and Stevens-Johnson syndrome are rare but serious risks. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

39/100

First-generation sodium channel blocker, proven and approved, long superseded as a novel research target

Look, carbamazepine is a 70-year-old drug that works. The mechanism, state-dependent voltage-gated sodium channel inhibition, was characterized decades ago and hasn’t gotten more interesting since. What carbamazepine does best is be reliable, and that reliability is precisely what limits its appeal as a live research target in 2024.

The evidence base is genuinely impressive, in the way that things that have been FDA-approved since 1968 tend to be. Hundreds of replicated trials for partial-onset seizures, tonic-clonic seizures, trigeminal neuralgia, and bipolar I mania. The translational arrow points straight down from bench to clinic because that work was done half a century ago. We’re not learning new things about carbamazepine; we’re using what we already know.

The differentiation story is the hard part. Oxcarbazepine was developed specifically to strip out carbamazepine’s worst liabilities, the potent CYP3A4 induction that wrecks contraceptive coverage and immunosuppressant dosing, the aplastic anemia and agranulocytosis risk, the SJS/TEN exposure in HLA-B*1502 carriers. Lacosamide took the sodium channel story in a more selective direction with slow-inactivation preference. Lamotrigine achieved a cleaner dual-mechanism profile with a better tolerability envelope. Carbamazepine retains the reference iminostilbene label, and thats genuinely useful for comparative class pharmacology. But if youre designing a new research program on voltage-gated sodium channels, you probably dont open with this one.

Honestly, where it still earns real bench credit is narrow but real. The auto-induction kinetics are a legitimate research model: the half-life collapses from 25-65 hours at first dose to 12-17 hours at steady state as it induces its own CYP3A4-mediated clearance, which makes it one of the cleaner in vivo models for studying auto-induction biology. The HLA-B*1502 pharmacogenomics work around SJS/TEN prediction in East and Southeast Asian populations is live research, and carbamazepine is the reference exposure for those studies. Those are real questions. They’re just not the kind of questions that drive high-priority bench allocations.

We think this belongs in the library as a reference standard and a pharmacogenomics model, not as a compound with active research momentum. A serious investigator looking for fresh signal in sodium channel pharmacology, CNS excitability, or mood stabilization would not prioritize carbamazepine in 2024. The science is largely settled. The score reflects that.

Novelty

12

Mechanism promise

20

In-category differentiation

28

Evidence quality

78

Translational signal

72

Research bench value

45

Rationale Carbamazepine scores high on evidence and translational signal because it is a fully approved drug with massive clinical literature, but novelty and mechanism promise are floor-level for a 1953 compound with a well-mapped, single-channel mechanism that newer agents have largely refined away. The reference probe angle gives it modest bench value, but this is not a compound generating new science.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Iminostilbene voltage-gated sodium channel blocker

A first-generation iminostilbene anticonvulsant and mood stabilizer with potent CYP3A4 induction.

Abstract

Carbamazepine (5H-dibenzo[b,f]azepine-5-carboxamide; CAS 298-46-4; molecular formula C15H12N2O; molecular weight 236.27) is an iminostilbene anticonvulsant developed by Walter Schindler at Geigy in 1953 and approved by the FDA in 1968 under the trade name Tegretol. Mechanism: state-dependent voltage-gated sodium channel inhibition (similar to lamotrigine), producing reduced neuronal hyperexcitability in seizure foci. Active metabolite carbamazepine-10,11-epoxide retains anticonvulsant activity. Plasma half-life is 25 to 65 hours initially but auto-induces own metabolism, dropping to 12 to 17 hours at steady state. Strong CYP3A4 induction produces clinically significant interactions with hormonal contraception, immunosuppressants, anticoagulants, antiretrovirals, and many other drugs. Approved for partial-onset and generalized tonic-clonic seizures, trigeminal neuralgia, and bipolar I mania (in combination products). The principal safety concerns are aplastic anemia and agranulocytosis (rare but serious; HLA-B*1502 association predicts SJS/TEN risk in Asian populations and is screened pretreatment). Used as the reference iminostilbene voltage-gated sodium channel blocker.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-244Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 46 47 48 49 50 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.